Q-omics provides the consensus-scored ARMH2 profile across patient tissues and cancer cell-line models. ARMH2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ARMH2 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, ARMH2 RNA expression shows 9,981 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, LUAD, and THYM as cancer lineages where ARMH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMH2 survival associations across molecular data types. ARMH2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMH2 RNA expression–survival associations across cancer types. High ARMH2 expression shows unfavorable associations in KICH, ACC, SKCM, MESO, LAML and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ARMH2 RNA expression.
This table summarizes ARMH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ARMH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMH2 shows lower tumor expression in LUAD, LUSC, THCA and COAD and higher tumor expression in CHOL and LIHC. The LUAD box plot shows higher ARMH2 RNA expression in normal versus tumor tissue (log2 FC = −1.196, t-test p < 0.001).
This table shows molecular features associated with ARMH2 in patient tissues and cancer cell lines. In patient samples, ARMH2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Myeloma.
